Cochrane · systematic review · CD009417
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
Sanders, SL, Agwan, S, Hassan, M, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 1 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSummary of findings table ‐ Immunoglobulins compared to placebo for children with respiratory syncytial virus infection
Population: children with respiratory syncytial virus infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (any cause during hospitalisation or Summary of findings table ‐ Immunoglobulins vs placebo | RR 0.87 [0.14, 5.27] | 4 studies · 309 participants | Very low Downgraded: risk of bias, imprecision |
Length of hospitalisation (days) Summary of findings table ‐ Immunoglobulins vs placebo | no estimate extracted | 6 studies · 737 participants | Moderate Downgraded: risk of bias |
Adverse events of any severity or seriousness Summary of findings table ‐ Immunoglobulins vs placebo | RR 1.18 [0.78, 1.78] | 5 studies · 340 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events Summary of findings table ‐ Immunoglobulins vs placebo | RR 1.08 [0.65, 1.79] | 4 studies · 238 participants | Low Downgraded: risk of bias, imprecision |